|
DNA ¹é½Å ½ÃÀå : Á¦Ç° À¯Çü, À¯Çü, ÃÖÁ¾»ç¿ëÀÚº° - ¼¼°è ±âȸ ºÐ¼® ¹× »ê¾÷ ¿¹Ãø(2021-2030³â)
DNA Vaccine Market by Product Type, Type, and End User : Global Opportunity Analysis and Industry Forecast, 2021-2030.
|
¸®¼Ä¡»ç |
Allied Market Research
|
¹ßÇàÀÏ |
2021³â 12¿ù |
»óǰÄÚµå |
1059611 |
ÆäÀÌÁö Á¤º¸ |
¿µ¹® 123 Pages
| ¹è¼Û¾È³» |
2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ) |
°¡°Ý |
|
DNA ¹é½Å ½ÃÀå : Á¦Ç° À¯Çü, À¯Çü, ÃÖÁ¾»ç¿ëÀÚº° - ¼¼°è ±âȸ ºÐ¼® ¹× »ê¾÷ ¿¹Ãø(2021-2030³â)
DNA Vaccine Market by Product Type, Type, and End User : Global Opportunity Analysis and Industry Forecast, 2021-2030.
|
¹ßÇàÀÏ : 2021³â 12¿ù | ÆäÀÌÁö Á¤º¸ : ¿µ¹® 123 Pages |
|
|
¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹®¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù. ¼¼°èÀÇ DNA ¹é½Å ½ÃÀå ±Ô¸ð´Â 2020³â 4¾ï 2,277¸¸ ´Þ·¯¿¡¼ ¿¹Ãø ±â°£ Áß 6.3%ÀÇ CAGR·Î ÃßÀÌÇϸç, 2030³â¿¡´Â 7¾ï 7,443¸¸ ´Þ·¯ ±Ô¸ð·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
DNA ¹é½Å ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î´Â Àΰ£ ¹× µ¿¹°¿¡¼ ¾Ï ¹× °¨¿°ÁõÀÇ À¯Çà, ³·Àº °¨¿° ¸®½ºÅ©, ¿î¼ÛÀÇ ¿ëÀ̼º, ½Ç¿Â¿¡¼ÀÇ ¾ÈÁ¤¼º µîÀÇ ÀÌÁ¡¿¡ ÀÇÇÑ DNA ¹é½Å ¼ö¿äÀÇ Áõ°¡ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ Ç×»ýÁ¦¿¡ ³»¼ºÀ» °¡Áø º´¿øÃ¼ÀÇ Áõ°¡¿¡ ÀÇÇØ Àå±âÀûÀÎ ¸é¿ª·ÂÀ» ÃÊ·¡ÇÏ´Â DNA ¹é½Å°ú °°Àº È¿°úÀûÀ̸ç Àúºñ¿ëÀÎ ¹é½Å Á¢Á¾ÀÇ Çʿ伺ÀÌ ¹ß»ýÇϸç DNA ¹é½Å ½ÃÀåÀÇ ¼ºÀåÀ» ÇÑÃþ ´õ Áö¿øÇϰí ÀÖ½À´Ï´Ù. ÇÑÆí, DNA ¹é½Å¿¡´Â ¸é¿ª¿ø¼ºÀÌ ¾øÀ¸¹Ç·Î ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇÒ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ DNA ¹é½ÅÀÇ Àΰ£¿¡ ´ëÇÑ ¿µÇâ¿¡ °üÇÑ Áö½ÄÀÌ ÇÑÁ¤µÇ¾î ÀÖ´Â °Íµµ ½ÃÀåÀÇ ¼ºÀåÀ» Á¦ÇÑÇÏ´Â ¿äÀÎÀÌ µÉ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù.
¼¼°èÀÇ DNA ¹é½Å ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ½ÃÀåÀÇ Á¤ÀÇ¿Í °³¿ä, ½ÃÀå ¿µÇâ¿äÀÎ ºÐ¼®, ½ÃÀå ±Ô¸ðÀÇ ÃßÀÌ¡¤¿¹Ãø, Á¦Ç° À¯Çü¡¤À¯Çü¡¤ÃÖÁ¾»ç¿ëÀÚ¡¤Áö¿ª/ÁÖ¿ä ±¹°¡ µî °¢Á¾ ºÎ¹®º° ³»¿ª, °æÀï ȯ°æ, ÁÖ¿ä ±â¾÷ÀÇ °³¿ä µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼·Ð
Á¦2Àå °³¿ä
Á¦3Àå ½ÃÀå °³¿ä
- ½ÃÀåÀÇ Á¤ÀÇ¡¤¹üÀ§
- ÁÖ¿ä Á¶»ç °á°ú
- PorterÀÇ »ê¾÷ ºÐ¼®
- ÁÖ¿ä ±â¾÷ÀÇ Æ÷Áö¼Å´×
- ½ÃÀå ¿ªÇÐ
- ÃËÁø¿äÀÎ
- ¾ïÁ¦¿äÀÎ
- ½ÃÀå ±âȸ
- ¿µÇ⠺м®
- COVID-19 : ¿µÇ⠺м®
- Àΰ£ DNA ¹é½Å
Á¦4Àå DNA ¹é½Å ½ÃÀå : Á¦Ç° À¯Çüº°
- °³¿ä
- Oncept
- West Nile-Innovator
- Apex-IHN
- ÁÖ¿ä ½ÃÀå µ¿Ç⡤¼ºÀå¿äÀΡ¤±âȸ
- ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ±¹°¡º°
- ½ÃÀå ºÐ¼® : ±¹°¡º°
Á¦5Àå DNA ¹é½Å ½ÃÀå : À¯Çüº°
- °³¿ä
- Ä¡·á¿ë ¹é½Å
- ¿¹¹æ ¹é½Å
- ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ±¹°¡º°
- ½ÃÀå ºÐ¼® : ±¹°¡º°
Á¦6Àå DNA ¹é½Å ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°
- °³¿ä
- ¼öÀÇ Å¬¸®´Ð
- ¼öÀÇ º´¿ø
- ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ±¹°¡º°
- ½ÃÀå ºÐ¼® : ±¹°¡º°
Á¦7Àå DNA ¹é½Å ½ÃÀå : Áö¿ªº°
- °³¿ä
- ºÏ¹Ì
- ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Á¦Ç° À¯Çüº°
- ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : À¯Çüº°
- ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°
Á¦8Àå ±â¾÷ °³¿ä
- BOEHRINGER INGELHEIM GmbH(MERIAL)
- ELI-LILLY(NOVARTIS ANIMAL HEALTH)
- GENEONE LIFE SCIENCE
- GEOVAX LABS, INC.
- INOVIO PHARMACEUTICALS(VGX ANIMAL HEALTH)
- GENEXINE, INC.
- VIATRIS INC.(ROTTAPHARM BIOTECH)
- TAKARA HOLDINGS(TAKARA BIO)
- ZOETIS INC.(FORT DODGE ANIMAL HEALTH)
- ZYDUS CADILA
KSA 22.03.08
LIST OF TABLES
- TABLE 01.GLOBAL DNA VACCINES MARKET, BY PRODUCT TYPE, 2020-2030($MILLION)
- TABLE 02.DNA VACCINE MARKET FOR ONCEPT, BY COUNTRY, 2020-2030($MILLION)
- TABLE 03.DNA VACCINE MARKET FOR WEST NILE-INNOVATOR, BY COUNTRY, 2020-2030($MILLION)
- TABLE 04.DNA VACCINE MARKET FOR APEX-IHN, BY COUNTRY, 2020-2030($MILLION)
- TABLE 05.GLOBAL DNA VACCINE MARKET, BY TYPE, 2020-2030($MILLION)
- TABLE 06.DNA VACCINE MARKET FOR THERAPEUTIC VACCINE, BY COUNTRY, 2020-2030($MILLION)
- TABLE 07.DNA VACCINE MARKET FOR PROPHYLACTIC VACCINES, BY COUNTRY, 2020-2030($MILLION)
- TABLE 08.GLOBAL DNA VACCINE MARKET, BY END USER, 2020-2030($MILLION)
- TABLE 09.DNA VACCINE MARKET FOR VETERINARY CLINICS, BY COUNTRY, 2020-2030($MILLION)
- TABLE 10.DNA VACCINE MARKET FOR VETERINARY HOSPITALS, BY COUNTRY, 2020-2030($MILLION)
- TABLE 11.NORTH AMERICA DNA VACCINE MARKET, BY COUNTRY, 2020-2030($MILLION)
- TABLE 12.U.S. DNA VACCINE MARKET, BY PRODUCT TYPE, 2020-2030($MILLION)
- TABLE 13.U.S. DNA VACCINE MARKET, BY TYPE, 2020-2030($MILLION)
- TABLE 14.U.S. DNA VACCINE MARKET, BY END USER, 2020-2030($MILLION)
- TABLE 15.CANADA DNA VACCINE MARKET, BY PRODUCT TYPE, 2020-2030($MILLION)
- TABLE 16.CANADA DNA VACCINE MARKET, BY TYPE, 2020-2030($MILLION)
- TABLE 17.CANADA DNA VACCINE MARKET, BY END USER, 2020-2030($MILLION)
- TABLE 18.NORTH AMERICA DNA VACCINE MARKET, BY PRODUCT TYPE, 2020-2030($MILLION)
- TABLE 19.NORTH AMERICA DNA VACCINE MARKET, BY TYPE, 2020-2030($MILLION)
- TABLE 20.NORTH AMERICA DNA VACCINE MARKET, BY END USER, 2020-2030($MILLION)
- TABLE 21.BOEHRINGER: COMPANY SNAPSHOT
- TABLE 22.BOEHRINGER: OPERATING SEGMENTS
- TABLE 23.BOEHRINGER: PRODUCT PORTFOLIO
- TABLE 24.LILLY:COMPANY SNAPSHOT
- TABLE 25.LILLY: OPERATING SEGMENTS
- TABLE 26.LILLY: PRODUCT PORTFOLIO
- TABLE 27.GENEONE : COMPANY SNAPSHOT
- TABLE 28.LILLY: OPERATING SEGMENTS
- TABLE 29.GENEONE: PRODUCT PORTFOLIO
- TABLE 30.GEOVAX: COMPANY SNAPSHOT
- TABLE 31.GEOVAX: OPERATING SEGMENTS
- TABLE 32.GEOVAX: PRODUCT PORTFOLIO
- TABLE 33.INOVIO: COMPANY SNAPSHOT
- TABLE 34.INOVIO: OPERATING SEGMENTS
- TABLE 35.INOVIO: PRODUCT PORTFOLIO
- TABLE 36.GENEXINE, INC.: COMPANY SNAPSHOT
- TABLE 37.GENEXINE, INC: OPERATING SEGMENTS
- TABLE 38.GENEXINE, INC: PRODUCT PORTFOLIO
- TABLE 39.VIATRIS: COMPANY SNAPSHOT
- TABLE 40.VIATRIS : OPERATING SEGMENTS
- TABLE 41.VIATRIS: PRODUCT PORTFOLIO
- TABLE 42.TAKARA HOLDINGS: COMPANY SNAPSHOT
- TABLE 43.TAKARA BIO: OPERATING SEGMENTS
- TABLE 44.TAKARA HOLDINGS: PRODUCT PORTFOLIO
- TABLE 45.ZOETIS: COMPANY SNAPSHOT
- TABLE 46.ZOETIS: OPERATING SEGMENTS
- TABLE 47.ZOETIS: PRODUCT PORTFOLIO
- TABLE 48.CADILA: COMPANY SNAPSHOT
- TABLE 49.CADILA: OPERATING SEGMENTS
- TABLE 50.CADILA: PRODUCT PORTFOLIO
LIST OF FIGURES
- FIGURE 01.DNA VACCINE MARKET SEGMENTATION
- FIGURE 02.TOP INVESTMENT POCKETS
- FIGURE 03.LOW BARGAINING POWER OF SUPPLIERS
- FIGURE 04.MODERATE BARGAINING POWER OF BUYERS
- FIGURE 05.MODERATE THREAT OF SUBSTITUTES
- FIGURE 06.MODERATE THREAT OF NEW ENTRANTS
- FIGURE 07.HIGH INTENSITY OF RIVALRY
- FIGURE 08.TOP PLAYER POSITIONING, 2020
- FIGURE 09.IMPACT ANALYSIS
- FIGURE 10.HUMAN DNA VACCINE MARKET
- FIGURE 11.COMPARATIVE ANALYSIS OF DNA VACCINE MARKET FOR ONCEPT, BY COUNTRY, 2020 & 2030 (%)
- FIGURE 12.COMPARATIVE ANALYSIS OF DNA VACCINE MARKET FOR WEST NILE-INNOVATOR, BY COUNTRY, 2020 & 2030 (%)
- FIGURE 13.COMPARATIVE ANALYSIS OF DNA VACCINE MARKET FOR APEX-IHN, BY COUNTRY, 2020 & 2030 (%)
- FIGURE 14.COMPARATIVE ANALYSIS DNA VACCINE MARKET FOR THERAPEUTIC VACCINES, BY COUNTRY, 2020 & 2030 (%)
- FIGURE 15.COMPARATIVE ANALYSIS OF DNA VACCINE MARKET FOR PROPHYLACTIC VACCINES, BY COUNTRY, 2020 & 2030 (%)
- FIGURE 16.COMPARATIVE ANALYSIS OF DNA VACCINE MARKET FOR VETERINARY CLINICS, BY COUNTRY, 2020 & 2030 ($MILLION)
- FIGURE 17.COMPARATIVE ANALYSIS OF DNA VACCINE MARKET FOR VETERINARY HOSPITALS, BY COUNTRY, 2020 & 2030 (%)
- FIGURE 18.BOEHRINGER: REVENUE, 2018-2020 ($MILLION)
- FIGURE 19.BOEHRINGER: REVENUE SHARE BY SEGMENT, 2020 (%)
- FIGURE 20.BOEHRINGER: REVENUE SHARE BY REGION, 2020 (%)
- FIGURE 21.LILLY: NET SALES 2018- 2020 ($MILLION)
- FIGURE 22.LILLY: REVENUE SHARE BY REGION, 2020 (%)
- FIGURE 23.GEOVAX: NET SALES 2018- 2020 ($MILLION)
- FIGURE 24.INOVIO: NET SALES, 2018-2020, ($MILLION)
- FIGURE 25.VIATRIS: NET SALES, 2018-2020 ($MILLION)
- FIGURE 26.VIATRIS: REVENUE SHARE BY SEGMENT, 2020 (%)
- FIGURE 27.VIATRIS: REVENUE SHARE BY REGION, 2020 (%)
- FIGURE 28.TAKARA HOLDINGS: NET SALES, 2019-2021, ($MILLION)
- FIGURE 29.TAKARA HOLDINGS: REVENUE SHARE BY SEGMENT, 2021 (%)
- FIGURE 30.ZOETIS: NET SALES, 2018-2020 ($MILLION)
- FIGURE 31.ZOETIS: REVENUE SHARE BY PRODUCT, 2020 (%)
- FIGURE 32.ZOETIS: REVENUE SHARE BY REGION, 2020(%)
- FIGURE 33.CADILA: NET SALES, 2019-2021 ($MILLION)
- FIGURE 34.CADILA: REVENUE SHARE BY SEGMENT, 2021 (%)
- FIGURE 35.CADILA: REVENUE SHARE BY REGION, 2021 (%)
The global DNA vaccine market was valued at $422.77 million in 2020 and is projected to reach $774.43 million by 2030 registering a CAGR of 6.3% from 2021 to 2030.
DNA vaccines is a small, circular DNA plasmid that encodes one or more protein antigens under the control of a promoter to produce a specific immune response against disease. DNA vaccines are the third-generation vaccines specifically designed to overcome the unsought properties of conventional vaccines. Increase in vulnerability of the population to infectious diseases and rise in number of antibiotics-resistant pathogens have created the need for effective and low-cost vaccination, which would provide long-lasting immunity.
The main driving factors of the DNA vaccines market include, rise in prevalence of cancer and infectious diseases in humans and animals, increase in demand for DNA vaccines owing to its advantages such as low risk of infection, easy transportation and stability at room temperature. In addition, increase in number of antibiotics resistant pathogens has created the need for effective and low-cost vaccination such as DNA vaccines, which would provide long lasting immunity, further boost growth of the DNA vaccines market.
However, lack of immunogenicity associated with DNA vaccines may hamper the growth of the market. Furthermore, limited knowledge of the effects of DNA vaccines on humans is also expected to limit the growth of the market. In contrast, development of novel vaccines using DNA technology, and high growth potential in untapped emerging economies are some factors that are expected to offer lucrative growth opportunities for players in the DNA vaccines market.
The global DNA vaccines market is segmented on the basis of product type, type, end user, and region to provide a detailed assessment of the market. By product type, it is segmented into Oncept, West Nile-Innovator, and Apex-IHN. By type, the market is segmented into therapeutic vaccines and prophylactic vaccines. Based on end user, it is categorized into veterinary clinics, veterinary hospitals. Region wise, the market is analyzed only across North America as DNA vaccine products have not been approved in the other regions.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the DNA vaccines market along with the current trends and future estimations to explain the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
- Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the key segments of the industry helps to understand the application and products of DNA vaccines used across the globe.
- Key market players and their strategies have been analyzed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
By Product Type
- Oncept
- West Nile-Innovator
- Apex-IHN
By Type
- Therapeutic Vaccines
- Prophylactic Vaccines
By End User
- Veterinary Clinics
- Veterinary Hospitals
By Region
- North America
- U.S.
- Canada
LIST OF KEY PLAYERS PROFILED IN THE REPORT
- BOEHRINGER INGELHEIM GmbH (Merial)
- ELI-LILLY (Novartis Animal Health)
- GeneOne Life Science
- GEOVAX LABS, INC
- Inovio Pharmaceuticals (VGX Animal Health)
- Genexine, Inc.
- VIATRIS INC. (Rottapharm Biotech)
- Takara Holdings (Takara Bio)
- ZOETIS INC. (Fort dodge Animal Health)
- Zydus Cadila
TABLE OF CONTENTS
CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key benefits for stakeholders
- 1.3.Key market segments
- 1.3.1.List of key players profiled in the report
- 1.4.Research methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.2.2.Top winning strategies
- 3.3.Porter's five force analysis
- 3.4.Top player positioning, 2020
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.1.1.Rise in prevalence of cancer and infectious diseases in humans and animals
- 3.5.1.2.Increase in demand for DNA vaccines
- 3.5.1.3.Growth in number of antibiotic resistant pathogens
- 3.5.2.Restraints
- 3.5.2.1.Lack of immunogenicity associated with DNA vaccines
- 3.5.2.2.Limited knowledge about the effects of DNA vaccines on humans
- 3.5.3.Opportunities
- 3.5.3.1.Development of novel vaccines using DNA technology
- 3.5.3.2.High growth potential in untapped emerging economies
- 3.5.4.Impact analysis
- 3.6.COVID-19 Impact analysis on the DNA vaccine market
- 3.7.Human DNA vaccine
CHAPTER 4:DNA VACCINE MARKET, BY PRODUCT TYPE
- 4.1.Overview
- 4.1.1.Market size and forecast
- 4.2.Oncept
- 4.2.1.Key market trends, growth factors, and opportunities
- 4.2.2.Market size and forecast, by country
- 4.2.3.Market analysis, by country
- 4.3.West Nile-Innovator
- 4.3.1.Key market trends, growth factors, and opportunities
- 4.3.2.Market size and forecast, by country
- 4.3.3.Market analysis, by country
- 4.4.Apex-IHN
- 4.4.1.Key market trends, growth factors, and opportunities
- 4.4.2.Market size and forecast, by country
- 4.4.3.Market analysis, by country
CHAPTER 5:DNA VACCINE MARKET, BY TYPE
- 5.1.Overview
- 5.1.1.Market size and forecast
- 5.2.Therapeutic Vaccines
- 5.2.1.Market size and forecast, by country
- 5.2.2.Market analysis, by country
- 5.3.Prophylactic Vaccines
- 5.3.1.Market size and forecast, by country
- 5.3.2.Market analysis, by country
CHAPTER 6:DNA VACCINE MARKET, BY END USER
- 6.1.Overview
- 6.1.1.Market size and forecast
- 6.2.Veterinary Clinics
- 6.2.1.Market size and forecast, by country
- 6.2.2.Market analysis, by country
- 6.3.Veterinary Hospitals
- 6.3.1.Market size and forecast, by country
- 6.3.2.Market analysis, by country
CHAPTER 7:DNA VACCINE MARKET, BY REGION
- 7.1.Overview
- 7.2.North America
- 7.2.1.Key market trends, growth factors, and opportunities
- 7.2.2.Market size and forecast, by country
- 7.2.2.1.U.S.
- 7.2.2.1.1.U.S. DNA vaccine market, by product type
- 7.2.2.1.2.U.S. DNA vaccine market, by type
- 7.2.2.1.3.U.S. DNA vaccine market, by end user
- 7.2.2.2.Canada
- 7.2.2.2.1.Canada DNA vaccine market, by product type
- 7.2.2.2.2.Canada DNA vaccine market, by type
- 7.2.2.2.3.Canada DNA vaccine market, by end user
- 7.2.3.North America market size and forecast, by product type
- 7.2.4.North America market size and forecast, by type
- 7.2.5.North America market size and forecast, by end user
CHAPTER 8:COMPANY PROFILES
- 8.1.BOEHRINGER INGELHEIM GmbH (MERIAL)
- 8.1.1.Company overview
- 8.1.2.Operating business segments
- 8.1.3.Product portfolio
- 8.1.4.Business performance
- 8.2.ELI-LILLY (NOVARTIS ANIMAL HEALTH)
- 8.2.1.Company overview
- 8.2.2.Company snapshot
- 8.2.3.Operating business segments
- 8.2.4.Product portfolio
- 8.2.5.Business performance
- 8.3.GENEONE LIFE SCIENCE
- 8.3.1.Company overview
- 8.3.2.Company snapshot
- 8.3.3.Operating business segments
- 8.3.4.Product portfolio
- 8.4.GEOVAX LABS, INC.
- 8.4.1.Company overview
- 8.4.2.Company snapshot
- 8.4.3.Operating business segments
- 8.4.4.Product portfolio
- 8.4.5.Business performance
- 8.5.INOVIO PHARMACEUTICALS (VGX ANIMAL HEALTH)
- 8.5.1.Company overview
- 8.5.2.Company snapshot
- 8.5.3.Operating business segments
- 8.5.4.Product portfolio
- 8.5.5.Business performance
- 8.6.GENEXINE, INC.
- 8.6.1.Company overview
- 8.6.2.Company snapshot
- 8.6.3.Operating business segments
- 8.6.4.Product portfolio
- 8.7.VIATRIS INC. (ROTTAPHARM BIOTECH)
- 8.7.1.Company overview
- 8.7.2.Company snapshot
- 8.7.3.Operating business segments
- 8.7.4.Product Portfolio
- 8.7.5.Business performance
- 8.8.TAKARA HOLDINGS (TAKARA BIO)
- 8.8.1.Company overview
- 8.8.2.Company snapshot
- 8.8.3.Operating business segments
- 8.8.4.Product portfolio
- 8.8.5.Business performance
- 8.9.ZOETIS INC. (FORT DODGE ANIMAL HEALTH)
- 8.9.1.Company overview
- 8.9.2.Company snapshot
- 8.9.3.Operating business segments
- 8.9.4.Product portfolio
- 8.9.5.Business performance
- 8.10.ZYDUS CADILA
- 8.10.1.Company overview
- 8.10.2.Company snapshot
- 8.10.3.Operating business segments
- 8.10.4.Product portfolio
- 8.10.5.Business performance
- 8.10.6.Key strategic moves and developments
|

|
¼¼°èÀÇ Ä¡·á¿ë ¹é½Å ½ÃÀå : ¹é½Å À¯Çüº°(Ç׿ø ¹é½Å, DNA ¹é½Å, ¼öÁö»ó¼¼Æ÷ ¹é½Å), ¹é½Å Á¶¼º ¹æ¹ýº°(Àڱ⠹é½Å, µ¿Á¾ ¹é½Å), Ä¡·á À¯Çüº°(´ÜÀÏ Á¦Á¦ Ä¡·á, º´¿ë Ä¡·á)
¾ç½Ä¾î¿ë ¹é½Å ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® : Á¦Ç°(ºÒÈ°È ¹é½Å, DNA ¹é½Å), Åõ¿© °æ·Î(ÁÖ»ç, °æ±¸), ¿ëµµ(¼¼±Õ, ¹ÙÀÌ·¯½º), Áö¿ªº°
¿¹Ãø(2021-2028³â)
DNA ¹é½Å : ±â¼ú ¹× ¼¼°è ½ÃÀå
¼¼°èÀÇ DNA ¹é½Å ½ÃÀå(2021-2027³â)
¼¼°èÀÇ DNA ¹é½Å ½ÃÀå Àü¸Á(2022³â)
¼¼°èÀÇ Àΰ£ DNA ¹é½Å ½ÃÀå : ±Ô¸ð, »óȲ, ¿¹Ãø
¼¼°èÀÇ DNA ¹é½Å ½ÃÀå(2019³â)
|